578 Shares in Intuitive Surgical, Inc. (NASDAQ:ISRG) Purchased by Hoxton Planning & Management LLC

Key Points

• Hoxton Planning & Management LLC has acquired a new position in Intuitive Surgical, Inc. by purchasing 578 shares valued at approximately $286,000.
• Several hedge funds have increased their stakes in Intuitive Surgical, with notable boosts from Invesco Ltd. (7.7% increase) and GAMMA Investing LLC (54,010.7% increase).
• Intuitive Surgical reported strong quarterly earnings, with $2.44 billion in revenue and $2.19 EPS, surpassing analyst expectations.

Hoxton Planning & Management LLC purchased a new position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 578 shares of the medical equipment provider's stock, valued at approximately $286,000.

A number of other hedge funds have also bought and sold shares of ISRG. Invesco Ltd. boosted its stake in shares of Intuitive Surgical by 7.7% in the 4th quarter. Invesco Ltd. now owns 4,148,180 shares of the medical equipment provider's stock valued at $2,165,184,000 after purchasing an additional 295,025 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Intuitive Surgical by 15.8% in the 4th quarter. Northern Trust Corp now owns 3,619,293 shares of the medical equipment provider's stock valued at $1,889,126,000 after purchasing an additional 494,496 shares in the last quarter. Capital Research Global Investors boosted its stake in shares of Intuitive Surgical by 25.5% in the 4th quarter. Capital Research Global Investors now owns 3,381,302 shares of the medical equipment provider's stock valued at $1,764,904,000 after purchasing an additional 687,906 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of Intuitive Surgical by 54,010.7% in the 1st quarter. GAMMA Investing LLC now owns 3,028,576 shares of the medical equipment provider's stock valued at $14,999,630,000 after purchasing an additional 3,022,979 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Intuitive Surgical by 12.8% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,826,972 shares of the medical equipment provider's stock valued at $1,475,566,000 after purchasing an additional 319,694 shares in the last quarter. 83.64% of the stock is owned by institutional investors.

Insider Activity at Intuitive Surgical

In other news, SVP Mark Brosius sold 216 shares of the business's stock in a transaction on Friday, June 6th. The shares were sold at an average price of $563.11, for a total transaction of $121,631.76. Following the sale, the senior vice president owned 907 shares in the company, valued at approximately $510,740.77. The trade was a 19.23% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Gary S. Guthart sold 2,800 shares of the company's stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $495.24, for a total transaction of $1,386,672.00. Following the completion of the transaction, the insider owned 18,520 shares in the company, valued at approximately $9,171,844.80. The trade was a 13.13% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 15,903 shares of company stock worth $7,932,778 over the last quarter. Corporate insiders own 0.70% of the company's stock.

Wall Street Analyst Weigh In

ISRG has been the subject of a number of recent research reports. Piper Sandler restated an "overweight" rating and set a $595.00 price target (up previously from $575.00) on shares of Intuitive Surgical in a research note on Wednesday, July 23rd. Robert W. Baird lowered their price objective on shares of Intuitive Surgical from $600.00 to $575.00 and set an "outperform" rating on the stock in a report on Wednesday, April 23rd. Barclays lowered their price objective on shares of Intuitive Surgical from $684.00 to $635.00 and set an "overweight" rating on the stock in a report on Thursday, April 24th. Citigroup restated a "buy" rating and set a $650.00 price objective (up previously from $590.00) on shares of Intuitive Surgical in a report on Thursday, May 22nd. Finally, Royal Bank Of Canada upped their price objective on shares of Intuitive Surgical from $605.00 to $615.00 and gave the stock an "outperform" rating in a report on Wednesday, July 23rd. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and fifteen have given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $592.05.

Intuitive Surgical Stock Performance

ISRG stock opened at $481.09 on Friday. The company has a market capitalization of $172.46 billion, a PE ratio of 67.10, a price-to-earnings-growth ratio of 5.25 and a beta of 1.64. Intuitive Surgical, Inc. has a one year low of $425.00 and a one year high of $616.00. The company's 50 day moving average price is $525.14 and its two-hundred day moving average price is $533.73.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 EPS for the quarter, topping the consensus estimate of $1.93 by $0.26. Intuitive Surgical had a net margin of 28.51% and a return on equity of 14.56%. The company had revenue of $2.44 billion for the quarter, compared to the consensus estimate of $2.35 billion. During the same period in the previous year, the firm earned $1.78 earnings per share. The firm's revenue for the quarter was up 21.4% on a year-over-year basis. On average, research analysts predict that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.